These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 11877966)

  • 1. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2002; (1):19-22. PubMed ID: 11877966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
    Bogdanov AB; Luk'ianov IV; Veliev EI
    Urologiia; 2006; (5):59-63. PubMed ID: 17444154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
    Bogdanov AB; Luk'ianov IV; Veliev EI
    Urologiia; 2008; (6):44-9. PubMed ID: 19248599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
    Di Silverio F; Bosman C; Salvatori M; Albanesi L; Proietti Pannunzi L; Ciccariello M; Cardi A; Salvatori G; Sciarra A
    Eur Urol; 2005 Jan; 47(1):72-8; discussion 78-9. PubMed ID: 15582252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Luk'ianov AE; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (3):5-8. PubMed ID: 9644979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Benign prostatic hyperplasia. Finasteride controls progression of BPH].
    MMW Fortschr Med; 2000 Jun; 142(25):62-3. PubMed ID: 10920676
    [No Abstract]   [Full Text] [Related]  

  • 15. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia].
    Pytel' IuA; Vinarov AZ
    Urol Nefrol (Mosk); 1996; (4):25-7. PubMed ID: 8928344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of benign prostatic hyperplasia: a review.
    Magoha GA
    East Afr Med J; 1996 Jul; 73(7):453-6. PubMed ID: 8918007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P; Andersen JT; Wolf H
    Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.
    Girman CJ; Kolman C; Liss CL; Bolognese JA; Binkowitz BS; Stoner E
    Prostate; 1996 Aug; 29(2):83-90. PubMed ID: 8700804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.